At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities including Antibody Drug Conjugates (ADCs), Immuno-Oncology, bi-specific/multi-specific antibody and CAR-T platforms.  Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.

Today, our expansive oncology portfolio comprises of approved and investigational treatments for a wide range of blood and solid tumors. We are evaluating more than 20 investigational medicines in over 300 clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology. 

Founded in 2018, Acrotech Biopharma Inc. was formed as a global platform to commercialize innovative proprietary medications. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders. Acrotech aspires to be a patient focused, research-based organization that strives to launch treatments which are accessible to patients that need them. 

Agamon Health is an innovative health-tech company focused on improving patient adherence to follow-up recommendations by automating the processes that enhance the effectiveness of cancer screening, incidental finding programs, and other early disease detection efforts. The Agamon Health Coordinate platform is an enterprise solution that can improve follow-up care across the entire patient care journey, from imaging surveillance to treatment to survivorship care. It automates manual follow-up processes to eliminate patient care gaps, improve organizational productivity, and create new downstream revenue streams. For additional information, visit  agamonhealth.com

About American Oncology Network

American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 290 providers practicing across 21 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. For more information, please visit AONcology.com.

American Regent, Inc.®, a Daiichi Sankyo Group company, is an industry-leading injectable manufacturer. For over 50 years, American Regent has been developing, manufacturing, and supplying quality generic and branded injectables for healthcare providers. For more than 20 years, we have been a leader in IV iron therapy.

American Regent is committed to US-based manufacturing. To that end, over the last several years we have made significant investments in expanding and modernizing our manufacturing facilities in Ohio and New York. This expansion will nearly double our capacity and allow us to better serve our customers now and in the future.

Speed counts. Flexibility matters. Reliability and quality are paramount. Because patients should never have to wait for the medications they need.

Amneal Pharmaceuticals, headquartered in Bridgewater, New Jersey, is one of the largest and the fastest growing generics pharmaceutical manufacturers in the United States. Founded in 2002, Amneal now has more than 7,000 employees in North America, Europe, and Asia, working together to bring high quality affordable medicines to patients worldwide. Amneal has significantly expanded its portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas. 

Annexus Health is the leading healthcare technology company that is revolutionizing the patient access journey by delivering innovative solutions, including tech-enabled services, that reduce financial and administrative burdens to improve access, speed, and adherence to critical care.

We are a leading commercial pharmaceutical company bringing differentiated products to patients. We have a robust portfolio of branded prescription neurology, inflammation, pain, and oncology medications. The company has grown through business development including acquisitions, licensing, and mergers. We are looking to leverage our commercial excellence to be the partner of choice. 

The mission of AVBCC is to provide a forum for payers, providers, and the entire oncology team to consider and evaluate the cost–value issues particular to cancer treatments and its impact on patient care and outcomes. This unique focus is achieved through discussions and collaborations with those involved in evaluating therapies, treating patients, and paying for care.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 125 countries, and its innovative medicines are used by millions of patients worldwide. Please visit www.astrazeneca-us.com and follow us on social media @AstraZeneca.

athenahealth strives to cure complexity and simplify the practice of healthcare. Our innovative technology includes electronic health records, revenue cycle management, and patient engagement solutions that help healthcare providers, administrators, and practices eliminate friction for patients while getting paid efficiently. We’re inspired by our vision to create a thriving ecosystem that delivers accessible, high-quality, and sustainable healthcare for all. Learn more at athenahealth.com

AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients.

AVEO’s lead candidate, FOTIVDA^® (tivozanib), received U.S. Food and Drug Administration (FDA) approval in March 2021 for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies

BeaconMD is group purchasing organization dedicated to serving community providers across a wide variety of specialties such as neurology, oncology, immunology, gastroenterology, ophthalmology and urology. BeaconMD gives its provider-led clinic and infusion center members transparency into drug pricing data to help them make better decisions to manage their drug spend and to enhance their practice viability. Backed by the distribution and cold chain expertise of Morris & Dickson, BeaconMD provides a comprehensive, growth-focused solution for outpatient practices, infusion centers, and other alternate sites of care outside of the acute care hospital setting. For more information, go to www.beaconmd.com.

Blueprint Medicines is a global precision therapy company that aims to invent transformative medicines for people with cancer and blood disorders. Applying an approach that is both precise and agile, we seek to create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate our scientific innovation into a broad pipeline of important approved and investigational precision therapies aimed at addressed difficult-to-treat cancers and blood disorders. Today, we are delivering our approved medicines to patients in the United States, Europe and in other geographies ourselves or through our partners. In addition, we are globally advancing multiple programs for systemic mastocytosis, lung cancer, breast cancer, and other genomically defined cancers, and cancer immunotherapy. 

At Boehringer Ingelheim, we are committed to improving patients' lives and continuously strive to embed the patient's perspective, voice, and insights into all that we do. We succeed by understanding patients’ needs and meeting those needs with innovative medicines and best-in-class engagements, programs, and services.

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.

Canopy provides oncology practices with a comprehensive platform for all the care that happens between visits. Canopy’s multi-channel ePRO and remote triage system enables practices to identify and prioritize patients who need help, resolve their issues using intelligent software, and generate new reimbursement streams from programs like RTM, PCM, CCM, EOM and more. For more information, visit www.canopycare.us.

Caris Life Sciences® (Caris) is a leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms, Caris has created the large-scale, multi-modal database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.

Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of novel immunotherapies to treat cancer.

Corcept Therapeutics is a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. In oncology, cortisol may suppress apoptotic pathways, thereby reducing chemotherapy efficacy. Our lead candidate, relacorilant, a selective glucocorticoid antagonist, may enhance taxane efficacy through the inhibition of cortisol’s antiapoptotic effects at the GR and is being studied in ROSELLA, phase 3 trial in patients with platinum-resistant ovarian cancer (NCT05257408). Relacorilant is an investigational product and is not approved for therapeutic use.

CuraScript SD by Evernorth provides integrated delivery solutions for the safe & efficient distribution of specialty pharmaceuticals & associated medical supplies. We’ve been caring for those who care for more than a quarter of a century by supplying biologics, branded drugs, generics, vaccines, infused medications and ancillary supportive care products to a wide range of medical providers.

‍DeepScribe is ambient AI created for chronic and complex care, automatically documenting each patient visit and bringing real-time clinical and billing intelligence to the point of care. Integrated with oncology-specific EHRs like OncoEMR and iKnowMed, DeepScribe is the leading AI platform that has proven success in optimizing cancer care workflows. Working closely with oncology leaders, DeepScribe delivers custom AI solutions to ensure operational efficiency and clinician satisfaction. To see how DeepScribe brings the joy of care back to medicine, visit deepscribe.ai. 

Eagle Oncology strives to deliver novel & proprietary formulations of proven oncology products, giving patients and healthcare providers more choices. We also continue to invest in EAGLE CAN (Care and Access Network) a patient services program that supports our oncology portfolio. 

Eisai Inc. is a human health care (hhc) company dedicated to pursuing innovative research and simplifying the treatment journey to help improve the lives of people affected by cancer, Alzheimer’s disease and other neurodegenerative conditions. Everything we do is guided by the simple principle that patients and their families come first, and we have a responsibility to listen to and learn from them.

Our hhc mission is the shared purpose that connects us to those we serve. It creates a network of powerful relationships that enable us to identify, understand and address unmet needs and healthcare disparities as we work towards achieving societal good.

Eisai Inc. is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd. Our U.S. operations include discovery, research and development; manufacturing; global supply and logistics; and commercial activities.

To learn more, please visit https://us.eisai.com and connect with us on X and LinkedIn. For more information on our research, follow our dedicated neurology (LinkedIn  and X) and oncology (LinkedIn and X) pages.

Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. The majority of new cancer drugs recently approved for use in the U.S. were studied in clinical trials with FCS participation* and has been recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award. Trained in prestigious medical schools and research institutes, our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report.

Founded in 1984, Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy. Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff.

*Prior to approval

Founded more than 40 years ago as the first biotechnology company, Genentech is dedicated to the rigorous pursuit of science and the development and delivery of life-changing medicines for people facing serious diseases. Headquartered in South San Francisco, California and a proud member of the Roche Group, our community is united by a common purpose and sense of urgency to transform the future of healthcare. Learn more at gene.com.

GTC offers genomic profiling of DNA, cfDNA, RNA and cfRNA for both solid and hematologic cancers to communities everywhere. We have a turn-around time of 5-10 days and a QNS rate of less than 1%. Our cooperative model allows us to partner with laboratories, hospitals, oncology practices and medical professionals to share resources which create efficiencies in cost, turnaround time and quality. GTC’s testing is NY state approved and covered by Medicare and most insurances. Our RNA sequencing capabilities go beyond just the detection of fusions and include alternative splicing, gene expression, exon skipping, and more.

At Gilead, we set and achieve bold ambitions in our fight against the world’s most devastating diseases, driven by 
our purpose of making the world a healthier place for all people. Over the past 35+ years, our work has improved the 
health of millions of people worldwide with diseases and conditions including cancer, viral hepatitis, HIV and COVID-19. 

Today, we continue accelerating our efforts to cure more viral diseases and even certain cancers while leading the charge 
to end the HIV epidemic and working to provide patients with the best that scientific innovation can deliver. This includes 
new antiviral therapies, next-generation cancer treatments and medicines for inflammatory diseases. 

We are going further by investing in world-class science, working with partners who share our ambitions, expanding access 
and addressing societal barriers to care. Going further also means thinking broadly about our responsibilities to society, to
the communities we aim to serve and the environment in which we operate. At the heart of it all is our culture and our 
employees. We know that today’s ambitions lead to tomorrow’s breakthroughs. At Gilead, we are pursuing our ambitions 
with grit and passion, united in our commitment to improving the lives of patients and the health of the world for 
generations to come.

GSK is a focused, global biopharma company. Our purpose is to unite science, technology and talent to get ahead of disease together and positivity impact the health of billions of people.

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube. 

IMS is a nationwide distributor specializing in the alternate site market since 1994. We offer a wide range of disposable products for infusion, oncology, respiratory, enteral feeding, and cleanroom needs, along with flexible biomedical services including equipment rental and purchase options from top manufacturers for exceptional patient care.

Ipsen is a global biopharmaceutical company focused on innovation and specialty care, At Ipsen, we develop and commercialize medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Disease. Our focus in oncology is on some of the most difficult-to-treat cancers. We have a growing portfolio of therapies for solid tumors and in hematology aimed at improving the lives of people living with pancreatic cancer, follicular lymphoma, epithelioid sarcoma, gastrointestinal and pancreatic neuroendocrine tumors, and carcinoid syndrome. Every day, our more than 5,000 employees worldwide, including nearly 800 in North America, work diligently to improve lives around the world. For more information, please visit

www.ipsen.com/us

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. We are a leader in sleep disorders and epilepsy; further developing in movement disorders and PTSD; and focused on hematologic malignancies and solid tumors. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules, biologics, innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. Please visit www.jazzpharmaceuticals.com for more information.

At Kite, our singular focus is cell therapy to treat and cure cancer. Our goal is to bring the promise of cell therapy to as many eligible patients as possible who may benefit. 

We believe cell therapy has the ability to change the way cancer is treated. Our cell therapy technology uses the power of a patient's own immune system (their white blood cells) to target and attack their cancer cells. 

Our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives.

Labcorp is a global leader of Innovative and comprehensive laboratory services that helps doctors, hospital, pharmaceutical companies, researchers, and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. Learn more about us at www.labcorp.com

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit www.lantheus.com. 

LeanTaaS is the leading provider of AI-powered and cloud-based capacity management, staffing, and patient flow software and services for health systems. Our iQueue products for operating rooms, infusion centers, and inpatient units use Lean principles and AI/ML predictive and prescriptive analytics to forecast future demand based on historical data, recent pattern shifts, and real-time insights. They help staff and providers act quickly, confidently, and decisively in response to avoid operational bottlenecks before they happen. 

The result? Expensive assets are utilized better, hospital ROI improves, patient access increases, and clinicians work at the top of their license with reduced administrative burden. 

MiBA is the premier source for oncology insights, offering the industry's most accurate and diverse data to revolutionize clinical decision-making. With unmatched speed and actionable insights, MiBA transforms cancer research and patient care.

At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer.  The potential to bring new hope to people with cancer drives our purpose and our commitment.  As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.  

NeoGenomics is a premier cancer diagnostics company, specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP accredited and CLIA certified laboratories for full-service sample processing and analysis services throughout the US; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom.

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

At Oncentric, our vision is to transform the way oncology care is delivered by making advanced, personalized, and efficient cancer treatment accessible to all. We believe that oncology practices of all sizes should have access to the same level of cutting-edge technology and comprehensive support that large healthcare systems enjoy. Whether you’re a small clinic serving a local community or a large cancer center treating patients from across the region, Oncentric is here to ensure that you have everything you need to provide the best possible care.

ONCOassist is a free decision-support app for oncology professionals.

It is the only oncology app on the market with the required regulatory approval for use in hospital settings. With over 89,000 registered users globally, ONCOassist offers unique tools and content tailored specifically to oncology professionals.

OneOncology was founded by community oncologists, for community oncologists, with the mission of
improving the lives of everyone living with cancer. Our goal is to enable community oncology practices
to remain independent and to improve patient access to care in their communities, all at a lower cost
than in the hospital setting. OneOncology supports our platform of community oncology practices
through group purchasing, operational optimization, data analytics, practice growth, and clinical
innovation. Our 1,575 cancer care providers care for approximately 915,000 patients at more than 520
sites of care nationwide.

Organon is a global healthcare company with a vision to create a better and healthier every day. We believe in the potential of biosimilars, and we are dedicated to delivering biosimilars to the health care system today, tomorrow, and beyond. Through collaboration at every level, we get closer to unlocking the value that biosimilars can create. 

PatientPoint connects patients, healthcare providers and life sciences companies with the right content at key points of change when healthcare decisions are made. Our solutions are proven to influence patient behavior and improve health outcomes, driving value for all stakeholders. Across the nation's largest network of connected digital devices in 35,000 physician offices leverages our proven behavorial change content engine, PatientPoint solutions empower better health for more than 750 million patient visits each year.

Chemotherapy-induced alopecia not only affects body image and self-esteem but also compromises privacy, sometimes leading patients to refuse treatment. With over 25 years of experience, Paxman leads the way in scalp cooling technology, addressing one of chemotherapy's most feared side effects. 

The Paxman Scalp Cooling System (PSCS) is clinically proven to reduce hair loss and ensure hair regrowth, allowing patients some control over their treatment, maintaining privacy and promoting positive attitudes towards treatment. 

Investment in scientific testing and development has allowed Paxman to achieve the highest levels of clinical efficacy. We continue to support clinical trials and research to enhance its effectiveness. 

Reimbursement for treatment is now a reality, making it more accessible than ever before. 

Join Paxman as we strive to improve the lives of cancer patients worldwide. 

For more details, including reimbursement visit paxmanscalpcooling.com or email us at HCP@paxmanusa.com. 

Pfizer Oncology is at the forefront of a new era in cancer care. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives.

Pharmacosmos Therapeutics Inc. is a U.S. specialty pharmaceutical company dedicated to providing patient care through the commercialization of Monoferric^® (ferric derisomaltose) injection and through exceptional resources to support this treatment. We are the U.S. affiliate of the Denmark-based Pharmacosmos Group. Please visit us at www.monoferric.com to learn more.

PharmaEssentia Corporation, headquartered in Taiwan, with U.S. subsidiaries in Burlington and Bedford, MA, is a rapidly growing biopharmaceutical innovator. The company aims to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one approved product and a diversifying pipeline. Founded in 2003, the company is now expanding its global presence with operations in the U.S., Japan, China and Korea. Visit our website to learn more.

Prism Transparent Purchasing Organization (Prism TPO) is an independent drug purchasing network for community oncology practices. With a radically simple, transparent model, Prism cuts out over 80% of traditional pricing components such as retrospective distribution rebates — leaving only what’s upfront and predictable. As a partner of ONCare Alliance, Prism TPO continues to expand its reach, championing a future where drug purchasing is straightforward and trustworthy.

Haystack MRD™ by Quest Diagnostics® is a tumor-informed, next-generation minimal residual disease (MRD) test that detects ultralow levels of circulating tumor DNA (ctDNA) to uncover residual or recurrent disease with exquisite sensitivity. Based on more than 20 years of collaboration to advance technical and clinical development in liquid biopsy technologies by cancer genomics pioneers at Johns Hopkins School of Medicine, Haystack MRD's purpose-built, high-precision science delivers novel insights that can help shape personalized treatment decision-making and empower clinicians to improve patient lives. 

Qure4u is the award-winning, all-in-one digital solution that helps you win patients, automate workflows, and get paid faster. No other platform is as user-friendly for patients, providers, and staff. Patients can use any device without the need to log in. Providers and staff work inside their EHR, where one-click functionality makes tasks faster and more efficient.

We mean fast—register patients in less than 1 minute, with 50-60% of appointments self-scheduled by patients. Ninety percent of co-payments are collected pre-visit, and 95% of patients ROI quiz and find out.

The feedback speaks for itself—we received the most 5-star reviews on the athenahealth Marketplace for two years in a row, reflecting the value we bring to our customers.

• Easy-Access Tools: Self-scheduling, walk-in management, staff scheduling, and more.
• Scheduling Optimization: Tools like Booking Booster, which auto-fills canceled appointments.
• Automated Patient Arrival: Achieve 90% check-in from home, eliminate paper at the front desk, and enhance patient tracking and navigation.
• Communication Automation: Phone call automation with chatbot integration, secure text messaging, procedure care plans, and more.
• Robust Analytics: Analytics across the entire patient journey, enabling data-driven decision-making to enhance patient experiences and operational efficiency.

We’re reinventing what’s possible in healthcare, and we’re ready to start the conversation when you are.

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for serious diseases.  Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and product candidates in development.  Visit www.Regeneron.com to learn more.

RxVantage is transforming the way physicians and their practice teams make healthcare connections that elevate the practice of medicine. The only all-in-one provider-preferred engagement platform of its kind, RxVantage intelligently connects healthcare providers with resources, including the precise life sciences field experts, when they need them and in a manner that fits seamlessly into their workflow.

For more information, visit www.rxvantage.com.

SCIO Management Solutions provides innovative technology-based revenue cycle solutions designed to help oncology practices maximize financial performance. SCIO recognizes the complexities inherent in revenue cycle management for buy-and-bill specialty practices. Leveraging data-driven insights and operational best practices, SCIO has empowered thousands of physicians to enhance financial performance, mitigate revenue leakage, and optimize reimbursement processes resulting in millions of dollars in recovered revenue and cost savings.

About Us:
Smirta Innovations is a leading provider of cutting-edge solutions tailored specifically for oncology practices. Our mission is to empower cancer care providers with tools that streamline operations, optimize workflows, and enhance patient care. By leveraging data-driven insights and advanced technology, we aim to improve the efficiency and effectiveness of oncology operations.

Our Flagship Product: OncoSmart®
OncoSmart® is an intelligent resource optimization platform designed to address common operational challenges faced by oncology practices. Currently implemented in over 80 centers, including infusion and radiology facilities, OncoSmart® has consistently delivered measurable results.

Key Features of OncoSmart®:

• iOptimize: Balances patient flow using real-time data to eliminate midday peaks and improve operational efficiency.
• iAssign: Automates nurse assignments based on patient acuity and staffing, ensuring balanced workloads and reducing burnout.
• iNtellisite: Provides actionable insights with data-driven KPIs, helping practices make informed decisions about staff, resources, and scheduling.

Benefits:

• Reduced staff burnout and improved nurse satisfaction.
• Enhanced patient flow and minimized delays.
• Maximized infusion room and resource utilization.
• Clear visibility into operational metrics for better decision-making.

Why Choose Smirta?
Smirta’s solutions are designed in collaboration with oncology professionals to meet the unique needs of cancer care providers. Our expertise, combined with a commitment to affordability and results, sets us apart from competitors. Whether you’re looking to address midday patient volume peaks, improve staff allocation, or streamline scheduling, OncoSmart® provides a proven path forward.

About Sobi North America

As the North American affiliate of international biopharmaceutical company Sobi, the Sobi North America team is committed to Sobi’s vision of being a leader in providing innovative treatments that transform lives for individuals with rare diseases. Our product portfolio includes multiple approved treatments focused on immunology, hematology and specialty care. With U.S. headquarters in the Boston area, Canadian headquarters in the Toronto area, and field sales, medical and market access representatives spanning North America, our growing team has a proven track record of commercial excellence. More information is available at https://www.sobi.com/usa or at www.sobi.com.

Stemline Therapeutics, a part of the Menarini Group, is focused on the development and commercialization of novel oncology therapeutics.

The goal of our dedicated team of scientists, specialists, researchers, and developers is to build a leading biopharmaceutical company focused on improving the lives of cancer patients by developing and commercializing novel first-in-class therapeutics.

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment.

Tempus AI, Inc. is a technology company leading the adoption of AI to advance precision medicine and patient care. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Unlimited Systems provides a platform for a wide range of specialty healthcare practices seeking measurable increases in staff productivity, cash flow, and revenue with Unlimited Financials. Unlimited Financials is a full-featured revenue cycle platform with detailed analytics and task-driven workflows from start to finish. Specialty healthcare practices using Unlimited Financials can be confident that they will achieve peak financial performance.

At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. We develop and deliver innovative cancer care technologies to support every step of the journey – from screening to survivorship. From advanced imaging and radiation therapy to comprehensive software and services, to interventional radiology, we are harnessing the power of our perspective while pursuing clinical research to create a more efficient, personalized care pathway for millions of patients each year.

VieCure is transforming oncology care with its patented AI-powered clinical decision support platform, ensuring community oncologists have real-time insights to deliver highly personalized, guideline-compliant treatment at scale. By combining cutting-edge technology with a patient-first approach, VieCure helps providers optimize care decisions, improve outcomes, and enhance operational efficiency. Through strategic partnerships and advanced technology, VieCure empowers oncology practices to streamline workflows and maximize reimbursement opportunities. Learn how VieCure is making a difference at www.viecure.com and connect with us on LinkedIn @VieCure. 

Zydus Pharmaceuticals (USA) Inc. is a division of Zydus Lifesciences Limited - a global healthcare provider for over 70 years. 

Our mission is to unlock new possibilities in life sciences by delivering high-quality healthcare solutions that impact lives.  We have grown into one of the leading generic pharmaceutical companies in the U.S., driven by our commitment to exceptional service for both customers and patients who rely on our products.

Zydus Pharmaceuticals continues to expand our portfolio in the U.S. market, introducing novel and innovative treatment options. This includes the first and only FDA-approved albumin solubilized docetaxel, BeizrayTM, a 505(b)(2) product, launching 2025

At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities including Antibody Drug Conjugates (ADCs), Immuno-Oncology, bi-specific/multi-specific antibody and CAR-T platforms.  Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.

Today, our expansive oncology portfolio comprises of approved and investigational treatments for a wide range of blood and solid tumors. We are evaluating more than 20 investigational medicines in over 300 clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology. 

Founded in 2018, Acrotech Biopharma Inc. was formed as a global platform to commercialize innovative proprietary medications. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders. Acrotech aspires to be a patient focused, research-based organization that strives to launch treatments which are accessible to patients that need them. 

Agamon Health is an innovative health-tech company focused on improving patient adherence to follow-up recommendations by automating the processes that enhance the effectiveness of cancer screening, incidental finding programs, and other early disease detection efforts. The Agamon Health Coordinate platform is an enterprise solution that can improve follow-up care across the entire patient care journey, from imaging surveillance to treatment to survivorship care. It automates manual follow-up processes to eliminate patient care gaps, improve organizational productivity, and create new downstream revenue streams. For additional information, visit  agamonhealth.com

About American Oncology Network

American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 290 providers practicing across 21 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. For more information, please visit AONcology.com.

American Regent, Inc.®, a Daiichi Sankyo Group company, is an industry-leading injectable manufacturer. For over 50 years, American Regent has been developing, manufacturing, and supplying quality generic and branded injectables for healthcare providers. For more than 20 years, we have been a leader in IV iron therapy.

American Regent is committed to US-based manufacturing. To that end, over the last several years we have made significant investments in expanding and modernizing our manufacturing facilities in Ohio and New York. This expansion will nearly double our capacity and allow us to better serve our customers now and in the future.

Speed counts. Flexibility matters. Reliability and quality are paramount. Because patients should never have to wait for the medications they need.

Amneal Pharmaceuticals, headquartered in Bridgewater, New Jersey, is one of the largest and the fastest growing generics pharmaceutical manufacturers in the United States. Founded in 2002, Amneal now has more than 7,000 employees in North America, Europe, and Asia, working together to bring high quality affordable medicines to patients worldwide. Amneal has significantly expanded its portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas. 

Annexus Health is the leading healthcare technology company that is revolutionizing the patient access journey by delivering innovative solutions, including tech-enabled services, that reduce financial and administrative burdens to improve access, speed, and adherence to critical care.

We are a leading commercial pharmaceutical company bringing differentiated products to patients. We have a robust portfolio of branded prescription neurology, inflammation, pain, and oncology medications. The company has grown through business development including acquisitions, licensing, and mergers. We are looking to leverage our commercial excellence to be the partner of choice. 

The mission of AVBCC is to provide a forum for payers, providers, and the entire oncology team to consider and evaluate the cost–value issues particular to cancer treatments and its impact on patient care and outcomes. This unique focus is achieved through discussions and collaborations with those involved in evaluating therapies, treating patients, and paying for care.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 125 countries, and its innovative medicines are used by millions of patients worldwide. Please visit www.astrazeneca-us.com and follow us on social media @AstraZeneca.

athenahealth strives to cure complexity and simplify the practice of healthcare. Our innovative technology includes electronic health records, revenue cycle management, and patient engagement solutions that help healthcare providers, administrators, and practices eliminate friction for patients while getting paid efficiently. We’re inspired by our vision to create a thriving ecosystem that delivers accessible, high-quality, and sustainable healthcare for all. Learn more at athenahealth.com

AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients.

AVEO’s lead candidate, FOTIVDA^® (tivozanib), received U.S. Food and Drug Administration (FDA) approval in March 2021 for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies

BeaconMD is group purchasing organization dedicated to serving community providers across a wide variety of specialties such as neurology, oncology, immunology, gastroenterology, ophthalmology and urology. BeaconMD gives its provider-led clinic and infusion center members transparency into drug pricing data to help them make better decisions to manage their drug spend and to enhance their practice viability. Backed by the distribution and cold chain expertise of Morris & Dickson, BeaconMD provides a comprehensive, growth-focused solution for outpatient practices, infusion centers, and other alternate sites of care outside of the acute care hospital setting. For more information, go to www.beaconmd.com.

Blueprint Medicines is a global precision therapy company that aims to invent transformative medicines for people with cancer and blood disorders. Applying an approach that is both precise and agile, we seek to create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate our scientific innovation into a broad pipeline of important approved and investigational precision therapies aimed at addressed difficult-to-treat cancers and blood disorders. Today, we are delivering our approved medicines to patients in the United States, Europe and in other geographies ourselves or through our partners. In addition, we are globally advancing multiple programs for systemic mastocytosis, lung cancer, breast cancer, and other genomically defined cancers, and cancer immunotherapy. 

At Boehringer Ingelheim, we are committed to improving patients' lives and continuously strive to embed the patient's perspective, voice, and insights into all that we do. We succeed by understanding patients’ needs and meeting those needs with innovative medicines and best-in-class engagements, programs, and services.

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.

Canopy provides oncology practices with a comprehensive platform for all the care that happens between visits. Canopy’s multi-channel ePRO and remote triage system enables practices to identify and prioritize patients who need help, resolve their issues using intelligent software, and generate new reimbursement streams from programs like RTM, PCM, CCM, EOM and more. For more information, visit www.canopycare.us.

Caris Life Sciences® (Caris) is a leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms, Caris has created the large-scale, multi-modal database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.

Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of novel immunotherapies to treat cancer.

Corcept Therapeutics is a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. In oncology, cortisol may suppress apoptotic pathways, thereby reducing chemotherapy efficacy. Our lead candidate, relacorilant, a selective glucocorticoid antagonist, may enhance taxane efficacy through the inhibition of cortisol’s antiapoptotic effects at the GR and is being studied in ROSELLA, phase 3 trial in patients with platinum-resistant ovarian cancer (NCT05257408). Relacorilant is an investigational product and is not approved for therapeutic use.

CuraScript SD by Evernorth provides integrated delivery solutions for the safe & efficient distribution of specialty pharmaceuticals & associated medical supplies. We’ve been caring for those who care for more than a quarter of a century by supplying biologics, branded drugs, generics, vaccines, infused medications and ancillary supportive care products to a wide range of medical providers.

‍DeepScribe is ambient AI created for chronic and complex care, automatically documenting each patient visit and bringing real-time clinical and billing intelligence to the point of care. Integrated with oncology-specific EHRs like OncoEMR and iKnowMed, DeepScribe is the leading AI platform that has proven success in optimizing cancer care workflows. Working closely with oncology leaders, DeepScribe delivers custom AI solutions to ensure operational efficiency and clinician satisfaction. To see how DeepScribe brings the joy of care back to medicine, visit deepscribe.ai. 

Eagle Oncology strives to deliver novel & proprietary formulations of proven oncology products, giving patients and healthcare providers more choices. We also continue to invest in EAGLE CAN (Care and Access Network) a patient services program that supports our oncology portfolio. 

Eisai Inc. is a human health care (hhc) company dedicated to pursuing innovative research and simplifying the treatment journey to help improve the lives of people affected by cancer, Alzheimer’s disease and other neurodegenerative conditions. Everything we do is guided by the simple principle that patients and their families come first, and we have a responsibility to listen to and learn from them.

Our hhc mission is the shared purpose that connects us to those we serve. It creates a network of powerful relationships that enable us to identify, understand and address unmet needs and healthcare disparities as we work towards achieving societal good.

Eisai Inc. is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd. Our U.S. operations include discovery, research and development; manufacturing; global supply and logistics; and commercial activities.

To learn more, please visit https://us.eisai.com and connect with us on X and LinkedIn. For more information on our research, follow our dedicated neurology (LinkedIn  and X) and oncology (LinkedIn and X) pages.

Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. The majority of new cancer drugs recently approved for use in the U.S. were studied in clinical trials with FCS participation* and has been recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award. Trained in prestigious medical schools and research institutes, our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report.

Founded in 1984, Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy. Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff.

*Prior to approval

Founded more than 40 years ago as the first biotechnology company, Genentech is dedicated to the rigorous pursuit of science and the development and delivery of life-changing medicines for people facing serious diseases. Headquartered in South San Francisco, California and a proud member of the Roche Group, our community is united by a common purpose and sense of urgency to transform the future of healthcare. Learn more at gene.com.

GTC offers genomic profiling of DNA, cfDNA, RNA and cfRNA for both solid and hematologic cancers to communities everywhere. We have a turn-around time of 5-10 days and a QNS rate of less than 1%. Our cooperative model allows us to partner with laboratories, hospitals, oncology practices and medical professionals to share resources which create efficiencies in cost, turnaround time and quality. GTC’s testing is NY state approved and covered by Medicare and most insurances. Our RNA sequencing capabilities go beyond just the detection of fusions and include alternative splicing, gene expression, exon skipping, and more.

At Gilead, we set and achieve bold ambitions in our fight against the world’s most devastating diseases, driven by 
our purpose of making the world a healthier place for all people. Over the past 35+ years, our work has improved the 
health of millions of people worldwide with diseases and conditions including cancer, viral hepatitis, HIV and COVID-19. 

Today, we continue accelerating our efforts to cure more viral diseases and even certain cancers while leading the charge 
to end the HIV epidemic and working to provide patients with the best that scientific innovation can deliver. This includes 
new antiviral therapies, next-generation cancer treatments and medicines for inflammatory diseases. 

We are going further by investing in world-class science, working with partners who share our ambitions, expanding access 
and addressing societal barriers to care. Going further also means thinking broadly about our responsibilities to society, to
the communities we aim to serve and the environment in which we operate. At the heart of it all is our culture and our 
employees. We know that today’s ambitions lead to tomorrow’s breakthroughs. At Gilead, we are pursuing our ambitions 
with grit and passion, united in our commitment to improving the lives of patients and the health of the world for 
generations to come.

GSK is a focused, global biopharma company. Our purpose is to unite science, technology and talent to get ahead of disease together and positivity impact the health of billions of people.

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube. 

IMS is a nationwide distributor specializing in the alternate site market since 1994. We offer a wide range of disposable products for infusion, oncology, respiratory, enteral feeding, and cleanroom needs, along with flexible biomedical services including equipment rental and purchase options from top manufacturers for exceptional patient care.

Ipsen is a global biopharmaceutical company focused on innovation and specialty care, At Ipsen, we develop and commercialize medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Disease. Our focus in oncology is on some of the most difficult-to-treat cancers. We have a growing portfolio of therapies for solid tumors and in hematology aimed at improving the lives of people living with pancreatic cancer, follicular lymphoma, epithelioid sarcoma, gastrointestinal and pancreatic neuroendocrine tumors, and carcinoid syndrome. Every day, our more than 5,000 employees worldwide, including nearly 800 in North America, work diligently to improve lives around the world. For more information, please visit

www.ipsen.com/us

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. We are a leader in sleep disorders and epilepsy; further developing in movement disorders and PTSD; and focused on hematologic malignancies and solid tumors. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules, biologics, innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. Please visit www.jazzpharmaceuticals.com for more information.

At Kite, our singular focus is cell therapy to treat and cure cancer. Our goal is to bring the promise of cell therapy to as many eligible patients as possible who may benefit. 

We believe cell therapy has the ability to change the way cancer is treated. Our cell therapy technology uses the power of a patient's own immune system (their white blood cells) to target and attack their cancer cells. 

Our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives.

Labcorp is a global leader of Innovative and comprehensive laboratory services that helps doctors, hospital, pharmaceutical companies, researchers, and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. Learn more about us at www.labcorp.com

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit www.lantheus.com. 

LeanTaaS is the leading provider of AI-powered and cloud-based capacity management, staffing, and patient flow software and services for health systems. Our iQueue products for operating rooms, infusion centers, and inpatient units use Lean principles and AI/ML predictive and prescriptive analytics to forecast future demand based on historical data, recent pattern shifts, and real-time insights. They help staff and providers act quickly, confidently, and decisively in response to avoid operational bottlenecks before they happen. 

The result? Expensive assets are utilized better, hospital ROI improves, patient access increases, and clinicians work at the top of their license with reduced administrative burden. 

MiBA is the premier source for oncology insights, offering the industry's most accurate and diverse data to revolutionize clinical decision-making. With unmatched speed and actionable insights, MiBA transforms cancer research and patient care.

At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer.  The potential to bring new hope to people with cancer drives our purpose and our commitment.  As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.  

NeoGenomics is a premier cancer diagnostics company, specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP accredited and CLIA certified laboratories for full-service sample processing and analysis services throughout the US; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom.

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

At Oncentric, our vision is to transform the way oncology care is delivered by making advanced, personalized, and efficient cancer treatment accessible to all. We believe that oncology practices of all sizes should have access to the same level of cutting-edge technology and comprehensive support that large healthcare systems enjoy. Whether you’re a small clinic serving a local community or a large cancer center treating patients from across the region, Oncentric is here to ensure that you have everything you need to provide the best possible care.

ONCOassist is a free decision-support app for oncology professionals.

It is the only oncology app on the market with the required regulatory approval for use in hospital settings. With over 89,000 registered users globally, ONCOassist offers unique tools and content tailored specifically to oncology professionals.

OneOncology was founded by community oncologists, for community oncologists, with the mission of
improving the lives of everyone living with cancer. Our goal is to enable community oncology practices
to remain independent and to improve patient access to care in their communities, all at a lower cost
than in the hospital setting. OneOncology supports our platform of community oncology practices
through group purchasing, operational optimization, data analytics, practice growth, and clinical
innovation. Our 1,575 cancer care providers care for approximately 915,000 patients at more than 520
sites of care nationwide.

Organon is a global healthcare company with a vision to create a better and healthier every day. We believe in the potential of biosimilars, and we are dedicated to delivering biosimilars to the health care system today, tomorrow, and beyond. Through collaboration at every level, we get closer to unlocking the value that biosimilars can create. 

PatientPoint connects patients, healthcare providers and life sciences companies with the right content at key points of change when healthcare decisions are made. Our solutions are proven to influence patient behavior and improve health outcomes, driving value for all stakeholders. Across the nation's largest network of connected digital devices in 35,000 physician offices leverages our proven behavorial change content engine, PatientPoint solutions empower better health for more than 750 million patient visits each year.

Chemotherapy-induced alopecia not only affects body image and self-esteem but also compromises privacy, sometimes leading patients to refuse treatment. With over 25 years of experience, Paxman leads the way in scalp cooling technology, addressing one of chemotherapy's most feared side effects. 

The Paxman Scalp Cooling System (PSCS) is clinically proven to reduce hair loss and ensure hair regrowth, allowing patients some control over their treatment, maintaining privacy and promoting positive attitudes towards treatment. 

Investment in scientific testing and development has allowed Paxman to achieve the highest levels of clinical efficacy. We continue to support clinical trials and research to enhance its effectiveness. 

Reimbursement for treatment is now a reality, making it more accessible than ever before. 

Join Paxman as we strive to improve the lives of cancer patients worldwide. 

For more details, including reimbursement visit paxmanscalpcooling.com or email us at HCP@paxmanusa.com. 

Pfizer Oncology is at the forefront of a new era in cancer care. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives.

Pharmacosmos Therapeutics Inc. is a U.S. specialty pharmaceutical company dedicated to providing patient care through the commercialization of Monoferric^® (ferric derisomaltose) injection and through exceptional resources to support this treatment. We are the U.S. affiliate of the Denmark-based Pharmacosmos Group. Please visit us at www.monoferric.com to learn more.

PharmaEssentia Corporation, headquartered in Taiwan, with U.S. subsidiaries in Burlington and Bedford, MA, is a rapidly growing biopharmaceutical innovator. The company aims to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one approved product and a diversifying pipeline. Founded in 2003, the company is now expanding its global presence with operations in the U.S., Japan, China and Korea. Visit our website to learn more.

Prism Transparent Purchasing Organization (Prism TPO) is an independent drug purchasing network for community oncology practices. With a radically simple, transparent model, Prism cuts out over 80% of traditional pricing components such as retrospective distribution rebates — leaving only what’s upfront and predictable. As a partner of ONCare Alliance, Prism TPO continues to expand its reach, championing a future where drug purchasing is straightforward and trustworthy.

Haystack MRD™ by Quest Diagnostics® is a tumor-informed, next-generation minimal residual disease (MRD) test that detects ultralow levels of circulating tumor DNA (ctDNA) to uncover residual or recurrent disease with exquisite sensitivity. Based on more than 20 years of collaboration to advance technical and clinical development in liquid biopsy technologies by cancer genomics pioneers at Johns Hopkins School of Medicine, Haystack MRD's purpose-built, high-precision science delivers novel insights that can help shape personalized treatment decision-making and empower clinicians to improve patient lives. 

Qure4u is the award-winning, all-in-one digital solution that helps you win patients, automate workflows, and get paid faster. No other platform is as user-friendly for patients, providers, and staff. Patients can use any device without the need to log in. Providers and staff work inside their EHR, where one-click functionality makes tasks faster and more efficient.

We mean fast—register patients in less than 1 minute, with 50-60% of appointments self-scheduled by patients. Ninety percent of co-payments are collected pre-visit, and 95% of patients ROI quiz and find out.

The feedback speaks for itself—we received the most 5-star reviews on the athenahealth Marketplace for two years in a row, reflecting the value we bring to our customers.

• Easy-Access Tools: Self-scheduling, walk-in management, staff scheduling, and more.
• Scheduling Optimization: Tools like Booking Booster, which auto-fills canceled appointments.
• Automated Patient Arrival: Achieve 90% check-in from home, eliminate paper at the front desk, and enhance patient tracking and navigation.
• Communication Automation: Phone call automation with chatbot integration, secure text messaging, procedure care plans, and more.
• Robust Analytics: Analytics across the entire patient journey, enabling data-driven decision-making to enhance patient experiences and operational efficiency.

We’re reinventing what’s possible in healthcare, and we’re ready to start the conversation when you are.

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for serious diseases.  Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and product candidates in development.  Visit www.Regeneron.com to learn more.

RxVantage is transforming the way physicians and their practice teams make healthcare connections that elevate the practice of medicine. The only all-in-one provider-preferred engagement platform of its kind, RxVantage intelligently connects healthcare providers with resources, including the precise life sciences field experts, when they need them and in a manner that fits seamlessly into their workflow.

For more information, visit www.rxvantage.com.

SCIO Management Solutions provides innovative technology-based revenue cycle solutions designed to help oncology practices maximize financial performance. SCIO recognizes the complexities inherent in revenue cycle management for buy-and-bill specialty practices. Leveraging data-driven insights and operational best practices, SCIO has empowered thousands of physicians to enhance financial performance, mitigate revenue leakage, and optimize reimbursement processes resulting in millions of dollars in recovered revenue and cost savings.

About Us:
Smirta Innovations is a leading provider of cutting-edge solutions tailored specifically for oncology practices. Our mission is to empower cancer care providers with tools that streamline operations, optimize workflows, and enhance patient care. By leveraging data-driven insights and advanced technology, we aim to improve the efficiency and effectiveness of oncology operations.

Our Flagship Product: OncoSmart®
OncoSmart® is an intelligent resource optimization platform designed to address common operational challenges faced by oncology practices. Currently implemented in over 80 centers, including infusion and radiology facilities, OncoSmart® has consistently delivered measurable results.

Key Features of OncoSmart®:

• iOptimize: Balances patient flow using real-time data to eliminate midday peaks and improve operational efficiency.
• iAssign: Automates nurse assignments based on patient acuity and staffing, ensuring balanced workloads and reducing burnout.
• iNtellisite: Provides actionable insights with data-driven KPIs, helping practices make informed decisions about staff, resources, and scheduling.

Benefits:

• Reduced staff burnout and improved nurse satisfaction.
• Enhanced patient flow and minimized delays.
• Maximized infusion room and resource utilization.
• Clear visibility into operational metrics for better decision-making.

Why Choose Smirta?
Smirta’s solutions are designed in collaboration with oncology professionals to meet the unique needs of cancer care providers. Our expertise, combined with a commitment to affordability and results, sets us apart from competitors. Whether you’re looking to address midday patient volume peaks, improve staff allocation, or streamline scheduling, OncoSmart® provides a proven path forward.

About Sobi North America

As the North American affiliate of international biopharmaceutical company Sobi, the Sobi North America team is committed to Sobi’s vision of being a leader in providing innovative treatments that transform lives for individuals with rare diseases. Our product portfolio includes multiple approved treatments focused on immunology, hematology and specialty care. With U.S. headquarters in the Boston area, Canadian headquarters in the Toronto area, and field sales, medical and market access representatives spanning North America, our growing team has a proven track record of commercial excellence. More information is available at https://www.sobi.com/usa or at www.sobi.com.

Stemline Therapeutics, a part of the Menarini Group, is focused on the development and commercialization of novel oncology therapeutics.

The goal of our dedicated team of scientists, specialists, researchers, and developers is to build a leading biopharmaceutical company focused on improving the lives of cancer patients by developing and commercializing novel first-in-class therapeutics.

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment.

Tempus AI, Inc. is a technology company leading the adoption of AI to advance precision medicine and patient care. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Unlimited Systems provides a platform for a wide range of specialty healthcare practices seeking measurable increases in staff productivity, cash flow, and revenue with Unlimited Financials. Unlimited Financials is a full-featured revenue cycle platform with detailed analytics and task-driven workflows from start to finish. Specialty healthcare practices using Unlimited Financials can be confident that they will achieve peak financial performance.

At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. We develop and deliver innovative cancer care technologies to support every step of the journey – from screening to survivorship. From advanced imaging and radiation therapy to comprehensive software and services, to interventional radiology, we are harnessing the power of our perspective while pursuing clinical research to create a more efficient, personalized care pathway for millions of patients each year.

VieCure is transforming oncology care with its patented AI-powered clinical decision support platform, ensuring community oncologists have real-time insights to deliver highly personalized, guideline-compliant treatment at scale. By combining cutting-edge technology with a patient-first approach, VieCure helps providers optimize care decisions, improve outcomes, and enhance operational efficiency. Through strategic partnerships and advanced technology, VieCure empowers oncology practices to streamline workflows and maximize reimbursement opportunities. Learn how VieCure is making a difference at www.viecure.com and connect with us on LinkedIn @VieCure. 

Zydus Pharmaceuticals (USA) Inc. is a division of Zydus Lifesciences Limited - a global healthcare provider for over 70 years. 

Our mission is to unlock new possibilities in life sciences by delivering high-quality healthcare solutions that impact lives.  We have grown into one of the leading generic pharmaceutical companies in the U.S., driven by our commitment to exceptional service for both customers and patients who rely on our products.

Zydus Pharmaceuticals continues to expand our portfolio in the U.S. market, introducing novel and innovative treatment options. This includes the first and only FDA-approved albumin solubilized docetaxel, BeizrayTM, a 505(b)(2) product, launching 2025